Holen Sie sich die Stockscreener-App
1.54
1.91%
-0.03
Handel nachbörslich:
1.54
Schlusskurs vom Vortag:
$1.57
Offen:
$1.55
24-Stunden-Volumen:
455.23K
Relative Volume:
0.50
Marktkapitalisierung:
$121.00M
Einnahmen:
$63.63M
Nettoeinkommen (Verlust:
$10.62M
KGV:
30.80
EPS:
0.05
Netto-Cashflow:
$-8.64M
1W Leistung:
+1.32%
1M Leistung:
+5.48%
6M Leistung:
-14.44%
1J Leistung:
+30.51%
1-Tages-Spanne:
$1.51
$1.58
1-Wochen-Bereich:
$1.51
$1.65
52-Wochen-Spanne:
$0.8214
$3.10
Protalix BioTherapeutics Inc. Stock (PLX) Company Profile
Firmenname
Protalix BioTherapeutics Inc.
Sektor
Branche
Telefon
972 4 988 9488
Adresse
2 Snunit Street, Science Park PO Box 455, Karmiel
Vergleichen Sie PLX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
PLX
Protalix BioTherapeutics Inc.
|
1.54 | 121.00M | 63.63M | 10.62M | -8.64M | 0.05 |
|
VRTX
Vertex Pharmaceuticals Inc
|
460.06 | 113.97B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
521.84 | 52.15B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
304.67 | 40.16B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
586.76 | 35.45B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
276.53 | 27.94B | 3.81B | -644.79M | -669.77M | -6.24 |
Protalix BioTherapeutics Inc. Stock (PLX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2020-06-08 | Bestätigt | H.C. Wainwright | Buy |
| 2017-04-17 | Bestätigt | Rodman & Renshaw | Buy |
| 2016-04-04 | Eingeleitet | Rodman & Renshaw | Buy |
| 2015-04-23 | Hochstufung | Jefferies | Hold → Buy |
| 2014-11-12 | Bestätigt | R. F. Lafferty | Buy |
| 2014-01-24 | Eingeleitet | R. F. Lafferty | Buy |
| 2012-05-02 | Herabstufung | Canaccord Genuity | Buy → Hold |
| 2012-05-02 | Bestätigt | Oppenheimer | Outperform |
| 2012-04-30 | Herabstufung | Auriga | Buy → Hold |
| 2011-10-13 | Eingeleitet | Morgan Joseph | Hold |
| 2011-03-17 | Herabstufung | WBB Securities | Strong Buy → Buy |
| 2010-11-09 | Bestätigt | Oppenheimer | Outperform |
| 2010-10-14 | Bestätigt | UBS | Buy |
| 2009-12-02 | Bestätigt | Hapoalim | Outperform |
| 2009-09-22 | Eingeleitet | Canaccord Adams | Buy |
| 2009-09-02 | Eingeleitet | Hapoalim | Outperform |
| 2008-12-01 | Bestätigt | Oppenheimer | Outperform |
| 2008-03-11 | Eingeleitet | UBS | Buy |
| 2007-11-20 | Eingeleitet | CIBC Wrld Mkts | Sector Outperform |
Alle ansehen
Protalix BioTherapeutics Inc. Aktie (PLX) Neueste Nachrichten
Squarepoint Ops LLC Buys 18,522 Shares of Protalix BioTherapeutics, Inc. (NYSE:PLX) - Defense World
Protalix BioTherapeutics, Inc. (NYSE:PLX) Shares Purchased by Millennium Management LLC - Defense World
Jane Street Group LLC Has $214,000 Stock Holdings in Protalix BioTherapeutics, Inc. (NYSE:PLX) - Defense World
Exploring Growth Opportunities In Protalix BioTherapeutics Inc (AMEX: PLX) - stocksregister.com
Northern Trust Corp Has $1.38 Million Stock Position in Protalix BioTherapeutics, Inc. (NYSE:PLX) - Defense World
Q1 Earnings Estimate for PLX Issued By HC Wainwright - Defense World
Protalix BioTherapeutics To Present At H.C. Wainwright BioConnect Conference; Webcast At 4:30 PM ET - Nasdaq
What is Zacks Small Cap’s Estimate for PLX Q2 Earnings? - Defense World
Protalix BioTherapeutics to Present at the 3rd Annual H.C. Wainwright BioConnect Investor Conference at Nasdaq NYC - Kilgore News Herald
Protalix BioTherapeutics to Present at the 3rd Annual H.C. Wainw - GuruFocus
PLX: First Quarter Results - MSN
Protalix BioTherapeutics (NYSE:PLX) Lowered to Buy Rating by StockNews.com - Defense World
Protalix BioTherapeutics targets phase 2 launch for PRX-115 in H2 2025 - MSN
Protalix BioTherapeutics, Inc. (AMEX:PLX) Q1 2025 Earnings Call Transcript - Insider Monkey
Protalix: Q1 Earnings Snapshot - New Haven Register
Protalix BioTherapeutics Inc (PLX) Q1 2025 Earnings Call Highlights: Revenue Surge and ... - Yahoo Finance
Protalix BioTherapeutics Inc (PLX) Q1 2025 Earnings Call Highlig - GuruFocus
Protalix BioTherapeutics Inc (PLX) Q1 2025 Earnings Call Highlights: Revenue Surge and ... By GuruFocus - Investing.com Canada
Earnings call transcript: Protalix Q1 2025 results miss forecasts, stock plunges - Investing.com
Protalix BioTherapeutics Reports Strong Q1 2025 Growth - TipRanks
Protalix BioTherapeutics (PLX) Sees Revenue Surge Amid Pipeline Advancements - GuruFocus
Small cap wrap: Protalix Biotherapeutics, Delivra Health, HIVE Digital, U.S. Global Investors... - Proactive financial news
Protalix BioTherapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2025 - marketscreener.com
Protalix eyes Phase II gout trial later this year following solid Q1 revenue growth - Proactive financial news
Protalix BioTherapeutics Reports First Quarter 2025 Financial and Business Results | PLX Stock News - GuruFocus
Protalix BioTherapeutics Inc Reports Q1 2025 Earnings: Revenue at $10.1M, Missing Estimates; EPS at -$0.05, Below Expectations - GuruFocus
Protalix BioTherapeutics Reports First Quarter 2025 Financial and Business Results - PR Newswire
Market Insight: Protalix BioTherapeutics Inc (PLX)’s Notable Drop, Closing at 2.73 - DWinneX
Protalix BioTherapeutics to Announce First Quarter 2025 Financial and Business Results on May 9, 2025 - The Malaysian Reserve
Protalix BioTherapeutics to Announce First Quarter 2025 Financia - GuruFocus
Protalix Earnings: Biotech Pioneer to Present Q1 2025 Results and Pipeline Updates May 9 - Stock Titan
Contrasting Genocea Biosciences (NASDAQ:GNCA) & Protalix BioTherapeutics (NYSE:PLX) - Defense World
Can you still get a good price for Protalix BioTherapeutics Inc (PLX) Shares at this point? - uspostnews.com
Fabry Disease Treatment Market Deep Research 2025-2032 | Idorsia Pharmaceuticals Ltd., Protalix BioTherapeutics - openPR.com
HC Wainwright Has Bullish Forecast for PLX Q1 Earnings - Defense World
A History of Outperforming Analyst Forecasts and Beating the Odds: Protalix BioTherapeutics Inc (PLX) - Sete News
Protalix stock soars to 52-week high, hits $3.04 - Investing.com
Protalix stock soars to 52-week high, hits $3.04 By Investing.com - Investing.com India
Monitoring Protalix BioTherapeutics Inc (PLX) after recent insider movements - knoxdaily.com
Protalix BioTherapeutics (PLX) Plans $100 Million Securities Off - GuruFocus
Fabry Disease Market: Epidemiology, Drugs, Companies, DelveInsight | Amicus Therapeutics, CHIESI Farmaceutici and Protalix Biotherapeutics, Sanofi (Genzyme), Takeda Pharmaceuticals, Sangamo Therapeuti - The Globe and Mail
Press Release Distribution & PR Platform - ACCESS Newswire
PLX’s earnings estimates: Are they on track to meet expectations? - uspostnews.com
Protalix BioTherapeutics Inc Inc. (PLX) Price Performance: A Technical Analysis Perspective - investchronicle.com
Protalix CFO Eyal Rubin to resign in six months By Investing.com - Investing.com India
Finanzdaten der Protalix BioTherapeutics Inc.-Aktie (PLX)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.12%
2.03%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):